European Agency Supports Advertising and marketing and marketing of Abrocitinib for AD
The Committee for Medicinal Products for Human Use of the European Medicines Agency has urged that the oral Janus kinase 1 inhibitor abrocitinib be granted marketing authorization in the European Union for treating atopic dermatitis (AD). The overall indication is for the…